Novo Nordisk is advancing its pricing strategy and formulation upgrades with increased assertiveness to recapture growth momentum in the obesity drug market. The company has introduced a higher-dose version of Wegovy, priced significantly below its main competitor.
Novo Nordisk stated that its new Wegovy HD injectable is priced at $399 per month for self-paying patients, approximately 40% lower than the cost of the top three dosages of Eli Lilly's Zepbound. As competition intensifies, this pricing strategy, combined with a more potent formulation, may signal a more forceful effort by Novo Nordisk to reestablish Wegovy's market position.
The drug officially launched on Tuesday with a 7.2 mg dose—three times stronger than the previous highest version—marking a major upgrade in Novo Nordisk's product strategy. Prior trial results showed Zepbound outperformed standard-dose Wegovy, helping Eli Lilly's drug become the most widely used obesity injection in the United States. Novo Nordisk's high-dose strategy may aim to narrow this perceived efficacy gap, while the lower price could improve accessibility for self-paying patients.
This launch is also part of Novo Nordisk's broader effort to expand its obesity drug portfolio through new formulations and pricing models. The oral version of Wegovy, introduced in January, has become the strongest-performing obesity drug launch to date. The company recently rolled out a subscription plan offering lower monthly fees for patients committing to multiple months of treatment. Wegovy HD will be available through Novo Nordisk's patient support program, traditional pharmacies, and select telehealth partners. Some subscription plans are expected to include the new formulation at standard rates, indicating that Novo Nordisk is adopting more flexible distribution strategies while strengthening its competitive position.
Comments